BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced that its leadership team will be speaking on panels at the following investor conferences in Q4 2024:
BioFuture 2024
Panel title: Real Use of AI in Pharma: Today and in the Near Future
Details: October 30, 2024, 11:00 am ET at CURE, New York, NY
Speaker: Kfir Schreiber, Co-Founder & CEO, DeepCure
UBS Global Technology Conference 2024
Panel title: AI Discovering Cures
Details: December 4, 2024, 2:15 pm MT at The Phoenician, Scottsdale, AZ
Speaker: Han Lim, Chief Business Officer, DeepCure
Piper Sandler 36th Annual Healthcare Conference
Panel title: AI in Drug Discovery and Development
Details: December 5, 2024, 2:00 pm ET at Lotte New York Palace, New York, NY
Speaker: Kfir Schreiber, Co-Founder & CEO, DeepCure
About DeepCure
DeepCure is a therapeutics company focused on advancing novel drugs with the potential to transform the treatment of inflammation and autoimmune diseases. The company was founded by researchers at MIT to accelerate breakthrough therapies using artificial intelligence (AI) and AI-enabling technologies for small molecule discovery. The company is based in Boston, MA, and its engineers, chemists, and biologists collaborate to find solutions to hard problems that will have an enormous impact on patient health. For more information, visit www.deepcure.ai.
